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Introduction {#sec1}
============

Frontotemporal dementia (FTD) refers to a group of neurodegenerative diseases caused by focal but progressive neuronal loss, astrogliosis, and spongiosis in the frontal and temporal cortices associated with abnormal intracellular accumulation of proteins, most commonly tau or TDP43 (TAR DNA-binding protein 43) ([@bib34], [@bib45]). Currently there are no effective disease-modifying therapies for FTD, making the treatment and prevention of FTD an area of significant unmet medical need.

Tau is expressed ubiquitously in the brain and locates predominantly in neuronal axons, where it regulates microtubule polymerization and guides the transport of proteins and organelles ([@bib36], [@bib43]). Alternative splicing of *MAPT* exons 2, 3, and 10 originates six tau isoforms that differ from one another by 29- or 58-amino-acid inserts at the N terminus, and by the presence of either three (3R-tau) or four (4R-tau) tandem-repeat sequences at the C terminus. Tau function and localization are regulated by post-translational modifications (PTMs); for example, phosphorylation, acetylation, and proteolysis ([@bib32], [@bib42], [@bib59]). In FTD, sporadic or autosomal dominant forms caused by *MAPT* mutations, inclusions containing hyperphosphorylated tau (P-tau) are detected within neurons and glia of affected brain regions.

Although these inclusions are key pathological features, the events leading to neuronal loss may start even earlier, but the tau species and precise molecular events causing cell death are poorly understood. Therefore it is crucial to investigate the early molecular events of disease, such as alterations in tau biochemistry and affected cellular pathways ([@bib18], [@bib32]). In this context, human induced pluripotent stem cell (iPSC)-derived neurons allow exploring the molecular basis of tau pathogenesis in a disease-relevant genetic background ([@bib15], [@bib23], [@bib29]).

Here, we investigated the underlying molecular and cellular mechanisms of pathogenicity associated with the rare tau variant A152T in a human neuronal context. Although the role of tau A152T in disease is still debated, it has been shown to affect tau function and PTMs, promote oligomerization and postmortem detection of inclusions, cause neuronal dysfunction independent of aggregation and neuroinflammation in animal models, and increase significantly the risk for FTD and other neurodegenerative diseases ([@bib8], [@bib33], [@bib37], [@bib38], [@bib40], [@bib12], [@bib47], [@bib56]). We utilized iPSCs derived from A152T carriers and derived neural progenitor cells (NPCs) and differentiated neuronal cells ([Figure 1](#fig1){ref-type="fig"}A). These cells represent ex vivo models of human neurons, with tau expression at endogenous physiologically relevant levels and in the context of the genomic background associated with disease. Overall, our results reveal potential targets for disease-modifying therapeutics to affect FTD and other tauopathies.

Results {#sec2}
=======

Human iPSC Lines {#sec2.1}
----------------

Cells from two individuals carrying the *MAPT* heterozygous variant A152T (c.1407G \> A; NCBI RefSeq [NM_001123066](ncbi-n:NM_001123066){#intref0010}; rs143624519) were studied. The first individual was diagnosed with a form of FTD, progressive supranuclear palsy, at the time of skin biopsy (FTD19, [Table S1](#mmc1){ref-type="supplementary-material"}), whose iPSCs were generated using standard retroviral vectors and the Yamanaka factors OCT3/4, SOX2, KLF4, and c-MYC ([@bib6]). The second was an asymptomatic individual (Tau6, [Table S1](#mmc1){ref-type="supplementary-material"}) whose iPSCs and neuronal phenotypes have been in part characterized by [@bib16]. Two age-matched individuals were also included as non-mutant controls: 8330-8 ([@bib51]) and CTR2-L17 ([@bib2]). Two iPSC clones from the first A152T carrier (19-L3, 19-L5), one clone from the second A152T carrier (Tau6-1), and two control iPSC clones (8330-8 and CTR2-L17) were selected for further studies ([Table S1](#mmc1){ref-type="supplementary-material"}).

All iPSCs had typical characteristics of PSCs ([@bib6], [@bib16]), including: colony-type morphology; expression of the stem cell surface marker SSEA-4 and pluripotency transcription factors OCT4/POU5F1 and NANOG ([Figure S1](#mmc1){ref-type="supplementary-material"}A); elevated expression of endogenous *OCT4*/*POU5F1*, *NANOG*, and the zinc-finger protein pluripotency marker *ZFP42*/*REX1*, relative to the corresponding fibroblasts ([Figure S1](#mmc1){ref-type="supplementary-material"}B); and ability for iPSC in vitro formation of embryoid bodies (EBs) and spontaneous differentiation of EBs into the three germ layers ectoderm (*TUJ1* expression), mesoderm (*SMA* expression), and endoderm (*AFP* expression) ([Figure S1](#mmc1){ref-type="supplementary-material"}C) ([@bib30]). Sanger sequencing of the *MAPT* locus confirmed the c.1407G \> A mutation in A152T iPSCs ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Preservation of normal karyotype was confirmed ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Based on cell proliferation, morphology, and ability to remain undifferentiated in culture over \>50 passages, there were no qualitative differences between control and A152T iPSCs.

Derivation and Characterization of Human NPCs {#sec2.2}
---------------------------------------------

NPC lines were generated from iPSCs through isolation of neural rosettes ([@bib44], [@bib57]) ([Table S1](#mmc1){ref-type="supplementary-material"}). Newly generated NPCs were immunopositive for the neural stem cell markers Nestin, SOX2, and Musashi-1, and the neuroepithelial marker PAX6 ([Figure 1](#fig1){ref-type="fig"}B), and were maintained in proliferative state under defined growth media with EGF (epidermal growth factor) and FGF (fibroblast growth factor ) ([Figure 1](#fig1){ref-type="fig"}A) ([@bib44], [@bib51], [@bib62]). Based on proliferation, cell morphology, and viability, there were no qualitative differences between control and A152T NPCs ([Figure 1](#fig1){ref-type="fig"}B).

NPC Differentiation into Neurons {#sec2.3}
--------------------------------

Based on an initial time-course analysis of NPC differentiation ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2F), we examined cortical and synaptic markers in 5-week neurons from two control and two A152T lines. Both control and A152T neurons expressed markers of the cortical layers II--VI, with some variability between cell lines ([Figure 1](#fig1){ref-type="fig"}C) that was not correlated with *MAPT* genotype ([Figure S2](#mmc1){ref-type="supplementary-material"}G), and comparable overall with a human anterior cingulate cortex (ACC) sample. Expression of cortical markers was also confirmed by immunofluorescence (IF) imaging of TBR1-, FEZF2-, CTIP2-, and FOXG1-positive neurons, with highest detection in the nucleus and cell body ([Figures 1](#fig1){ref-type="fig"}EI--1EIV). Expression of synaptic proteins PSD95, SYN1, and SYP was also detected at comparable levels in all neuronal cells ([Figures 1](#fig1){ref-type="fig"}D and [S2](#mmc1){ref-type="supplementary-material"}H), with appreciable detection in neuronal processes but greater detection in the cell body, as expected at an early stage of neuronal maturity ([Figures 1](#fig1){ref-type="fig"}EV and 1EVI). NeuN is a neuronal-specific nuclear/perinuclear protein and MAP2 is a microtubule-associated protein, both utilized as neuronal markers ([Figures 1](#fig1){ref-type="fig"}D and 1EVIII). The diversity of neuronal cell types obtained from NPC differentiation was examined based on expression of specific markers. We detected glutamatergic neurons, which are highly affected in FTD (VGLUT1, [Figures 1](#fig1){ref-type="fig"}EVII and [S3](#mmc1){ref-type="supplementary-material"}) ([@bib28]), as well as cholinergic, GABAergic, dopaminergic/adrenergic, and serotonergic neurons, in addition to glia, with no detection of neural crest or cardiomyocyte lineage cells ([Figure S3](#mmc1){ref-type="supplementary-material"}).

These results revealed that NPC-differentiated cells display neuron-specific morphology, and expression of protein markers reminiscent of in vivo neurogenesis and human cortical neurons. The variability captured between cell lines ([Figures 1](#fig1){ref-type="fig"}C and 1D) was mostly due to inherent differences between iPSC-derived clonal lines and was not correlated with *MAPT* genotype ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H).

Upregulation of Tau in A152T Neurons {#sec2.4}
------------------------------------

FTD-associated *MAPT* mutations, including the variant A152T, have been shown to promote accumulation of tau and neurodegeneration ([@bib33], [@bib38]). To explore whether this is an early disease-relevant molecular event in A152T neurons, we started by examining tau protein levels and PTMs. To this end, we utilized three NPC lines derived from the FTD19 A152T carrier (19-L3-RC3, 19-L5-RC6, and 19-L5-RC7), two NPC lines from the Tau6 A152T carrier (Tau6-1-RC1 and Tau6-1-RC2), and three control NPC lines (8330-8, 8330-8-RC1, and CTR2-L17-RC2) ([Table S1](#mmc1){ref-type="supplementary-material"}).

We first performed a time-course analysis of tau levels by western blot between proliferative state (week 0) and 5 weeks of differentiation, by employing a panel of seven tau and P-tau antibodies. By comparing averaged tau levels between controls and A152T lines, we detected a time-dependent increase in total tau levels (TAU5 and DA9 antibodies), with a more rapid tau upregulation in A152T neurons relative to control cells at 5 weeks of differentiation ([Figures 2](#fig2){ref-type="fig"}A--2C). These antibodies report on total protein independently of PTMs, which, together with alternative splicing isoforms, give rise to distinct molecular weight bands ([Figure 2](#fig2){ref-type="fig"}A, blue arrows). Recombinant human tau, consisting of a ladder of six tau isoforms without PTMs, was also included in the analysis to guide interpretation of band pattern, even though equivalent migration does not report on a particular endogenous tau isoform, given endogenous tau PTMs. TAU1 antibody that recognizes a form of non-P-tau (non-P-S199/S202/T205) corroborated overall tau upregulation in A152T neurons ([Figures 2](#fig2){ref-type="fig"}A and 2D). Further individual analysis of all cell lines at 5 weeks of differentiation revealed that, whereas FTD19-derived A152T neurons showed an upregulation of total tau, Tau6-1-derived neurons' total tau levels were more comparable with control after the same period of differentiation ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B).

Next, P-tau was examined with the antibodies AT8 (P-Ser202/Thr205), AT180 (P-Thr231/Ser235), PHF1 (P-Ser396/Ser404), and S396 (P-Ser396), which recognize phospho-epitopes associated with autosomal dominant forms of tauopathy ([@bib10], [@bib20]). The increase in P-tau levels was also time dependent and, whether analyzed between averaged controls versus A152T lines ([Figures 2](#fig2){ref-type="fig"}E--2I and [S4](#mmc1){ref-type="supplementary-material"}B inset) or individually ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B), all A152T neurons showed an upregulation of P-tau relative to controls. In particular, AT8 and AT180 tau were barely detected in control neurons ([Figures 2](#fig2){ref-type="fig"}F and 2G). Only PHF1 and S396 antibodies revealed tau species of high molecular weight (HMW; \>250 kDa) with specificity to A152T neurons (green arrows in [Figures 2](#fig2){ref-type="fig"}E and [S4](#mmc1){ref-type="supplementary-material"}A), indicating the presence of oligomeric, hyper-P-tau at the Ser396/Ser404 epitope. Even with some variability among clonal lines, our findings suggest tau upregulation in A152T neurons, particularly in the form of P-tau ([Figures 2](#fig2){ref-type="fig"}E--2I and [S4](#mmc1){ref-type="supplementary-material"}B). Semi-quantitative RT-PCR analysis revealed that *MAPT* expression was constant between control and A152T neurons (total *MAPT*, [Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D), and that 3R- and 4R-tau expression was also constant across cell lines, with higher 3R-tau levels, consistent with the immaturity of these 5-week neurons ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4E) ([@bib53]). These results suggest that upregulation of tau is a result of protein accumulation rather than altered gene expression. Subsequent studies are shown at 5 weeks of differentiation, unless noted otherwise, but all phenotypes were also validated up to 20 weeks of differentiation (not shown).

We next utilized IF to examine the subcellular distribution of tau and P-tau. A152T neurons, in particular FTD19-derived neurons, showed a stronger signal for total tau K9JA antibody in the cell body and neuronal processes relative to control (red in [Figures 3](#fig3){ref-type="fig"}I--3V). The distinction between A152T and control neurons was even more accentuated for P-tau PHF1 staining, which showed a weaker signal in control neurons, being almost absent in cell bodies, whereas A152T neurons showed strong PHF1 staining in cell body and neuronal processes (red in [Figures 3](#fig3){ref-type="fig"}VI--3X). Upon co-staining of tau (K9JA) and P-tau (PHF1), we observed a higher PHF1-to-K9JA (green-to-red) relative intensity in A152T neurons, with a stronger PHF1 signal in the cell body and neuronal processes of A152T neurons relative to control ([Figures 3](#fig3){ref-type="fig"}XI--3XV). We did not, however, detect foci-like tau staining, reminiscent of tau aggregates or tangles, and neurons were Thioflavin-S negative (not shown). Due to the high density of neuronal processes in these cultures, we were unable to use automated microscopy to accurately quantify subcellular tau levels.

Collectively, these results suggest that an early marker of A152T pathogenesis is an early and time-dependent accumulation of tau, predominantly in the form of P-tau and oligomeric P-tau. IF corroborated the accumulation of tau/P-tau in A152T neurons, further revealing increased P-tau in neuronal processes and cell body of A152T neurons, consistent with somatodendritic redistribution, both important pathophysiological features of tauopathy, detected here as an early phenotype in patient-derived neurons in vitro ([@bib11], [@bib16], [@bib39], [@bib56]).

Quantitative Analysis of Tau in Human Neurons by Mass Spectrometry {#sec2.5}
------------------------------------------------------------------

To corroborate our antibody-based results we employed FLEXITau, a mass spectrometry (MS)-based targeted assay for absolute quantification of tau protein levels and PTMs ([@bib41]). A schematic of this methodology is shown in [Figure 4](#fig4){ref-type="fig"}A, and in-depth details have been described ([@bib41], [@bib52]). FLEXITau absolute quantification of tau in control (8330-8-RC1) and A152T (19-L5-RC6) neurons at 5, 12, and 20 weeks of differentiation revealed upregulation of tau in A152T neurons, which was more pronounced at 20 weeks of differentiation (2.5-fold relative to control, average 28.5 fmol/μg and 11.4 fmol/μg protein lysate, respectively) ([Figure 4](#fig4){ref-type="fig"}B). Notably, the levels of tau in control neurons reached a plateau after 12 weeks, whereas A152T neurons showed a linear increase in tau levels up to 20 weeks of differentiation ([Figure 4](#fig4){ref-type="fig"}B, R^2^ = 0.999; not shown), again indicative of aberrant tau accumulation in A152T neurons.

Differential Expression of Non-mutant and A152T Tau {#sec2.6}
---------------------------------------------------

Given the lack of variant-specific antibodies to date, all studies of expression of endogenous mutant tau have relied on the inference that the mutated allele is expressed. However, this hindrance precludes gaining an understanding of the ratio between non-mutant and mutant protein levels and misinterpretation of total protein levels, because gene mutations can alter protein stability and biochemical properties. Therefore, we used a targeted MS approach to measure non-mutant and variant tau protein levels in control and A152T neurons (LysC digest, [Figure 4](#fig4){ref-type="fig"}A). Shotgun tandem MS (MS/MS) analysis from LysC-digested control and A152T neurons identified the peptides ~151~I**[A]{.ul}**TPRGAAPPGQK~163~ (non-mutant) and ~151~I**[T]{.ul}**TPRGAAPPGQK~163~ (A152T) by specific peptide fragment spectra ([Figure S5](#mmc1){ref-type="supplementary-material"}). For quantification of these peptides, we developed a targeted selected reaction monitoring (SRM) assay ([Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}), which showed that in A152T neurons the levels of A152T tau are higher (56.6%) than non-mutant tau (43.4%), and this ratio stayed constant over the time points analyzed ([Figure 4](#fig4){ref-type="fig"}C), even though overall levels of total tau increased ([Figure 4](#fig4){ref-type="fig"}B). This is the first demonstration and quantification of allele-specific expression of a tau variant protein in a human iPSC-derived neuronal model.

Tau PTMs and Isoforms by Mass Spectrometry {#sec2.7}
------------------------------------------

FLEXITau MS analysis also enables the characterization of *MAPT* splicing and tau PTMs ([@bib41]). This strategy relies on the quantification of unmodified tau peptides in a cell lysate relative to spiked-in stable isotope-labeled unmodified peptides derived from heavy-labeled tau protein. A reduction in cell lysate-measured light peptides is evidence of a "modification" in the endogenous tau peptide, and this modification can be a PTM, alternative splicing, or a mutation. We employed global FLEXITau analysis on 5-week neurons, using both trypsin and LysC samples to maximize sequence coverage ([Figure 4](#fig4){ref-type="fig"}A). The regions with the highest "modifications" were the exons that undergo alternative splicing (E2, E3, E10; [Figure 4](#fig4){ref-type="fig"}D). Within the sensitivity of our MS assay, the peptides corresponding to E2 and E3 were not detected, whereas E10 (4R-tau) was detected by one peptide ([Figure 4](#fig4){ref-type="fig"}D), corroborating gene-expression analysis ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4E) and predominance of the 0N3R isoform. FLEXITau also detected "modified" peptides within the proline-rich region and the C-terminal tail, probably corresponding to PTMs. The peptides harboring Ser202/Thr205 (AT8), Thr231/Ser235 (AT180), and Ser396/Ser404 (PHF1) epitopes showed a decrease in unmodified peptides, i.e., an increase in "modified" epitopes in A152T neurons relative to control (p = 0.013), consistent with increased P-tau ([Figure 4](#fig4){ref-type="fig"}D). As expected, in A152T neurons the non-mutant (unmodified) peptide that covers the A152 site (~151~I**[A]{.ul}**TPRGAAPPGQK~163~) was only 47.5% of the corresponding peptide in control neurons, as the remaining "modified" peptide harbors to A152T variant ([Figure 4](#fig4){ref-type="fig"}D).

One possible mechanism for the variant A152T to alter tau function ([@bib13]) would be by creating a new threonine (Thr/T) P-site. To test this, we attempted to quantify the P-peptide ~151~Ip**[T]{.ul}**TPRGAAPPGQK~163~ by SRM analysis, using a synthetic heavy P-peptide as a reference. We were unable to detect the endogenous light counterpart within the sensitivity range of our SRM assay (as low as 2.5 fmol/μL of endogenous tau, not shown), suggesting that in human iPSC-derived neurons, the variant A152T is unlikely to create a new phosphorylation site or, if it does, it is phosphorylated to less than 2.5% occupancy.

Reduced Tau Solubility in A152T Neurons {#sec2.8}
---------------------------------------

To determine whether accumulation of P-tau led to the formation of protein species of reduced solubility, a hallmark of tauopathy, we tested tau protein differential solubility to Triton X-100 and SDS detergents ([@bib21], [@bib22], [@bib35]). A152T neurons showed significantly more accumulation of Triton-insoluble total tau (TAU5) and P-tau (AT8, S396), i.e., SDS-fraction tau (S, [Figure 5](#fig5){ref-type="fig"}A). The HMW species (\>250 kDa) detected by the P-tau S396 antibody showed a mixture of detergent-soluble and -insoluble tau in A152T neurons, but only Triton-soluble tau in control neurons. When comparing only the insoluble fractions (S), A152T neurons showed a preferential accumulation of P-tau, which was particularly accentuated in FTD19-derived neurons ([Figure 5](#fig5){ref-type="fig"}B). These results suggest that accumulation of tau in A152T neurons leads to the formation of species of reduced solubility, which is likely to negatively affect cellular function.

Affected Proteostasis in FTD Neurons {#sec2.9}
------------------------------------

We examined whether upregulation of tau in A152T neurons affected proteostasis, which is kept by the concerted function of multiple pathways ([Figure 6](#fig6){ref-type="fig"}A), including the heat-shock response (HSR) and the ER and mitochondrial unfolded protein responses (UPR) that upregulate expression of molecular chaperones and other factors to prevent aberrant accumulation of proteins, and the ubiquitin proteasome system (UPS) and autophagy-lysosomal pathways responsible for clearance of these proteins ([@bib3], [@bib60]). We asked whether these pathways were affected in A152T neurons by measuring pathway-specific components ([Figure 6](#fig6){ref-type="fig"}A, in blue). We examined 8-week differentiated neurons to take advantage of time-dependent accumulation of tau.

Relative to control, A152T neurons showed an increase in polyubiquitinated proteins (UBI1), which accumulate when UPS is disrupted, as well as an upregulation of autophagy markers (LC3B-II, ATG12/5, SQSTM1/p62, LAMP1, and LAMP2a), revealing activation of autophagy in A152T neurons ([Figures 6](#fig6){ref-type="fig"}B, 6F, 6D, and 6I). In contrast, there was no significant HSP70 chaperone family (HSP70, CHIP, HIP, and HOP) or HSP90 upregulation, suggesting no HSR induction ([Figures 6](#fig6){ref-type="fig"}C and 6G). To examine oxidative stress, we measured the levels of carbonylated proteins that accumulate in the cell by excessive protein oxidation ([Figure 6](#fig6){ref-type="fig"}D) ([@bib9]). A152T neurons showed a modest increase in stable 2,4-dinitrophenylhydrazone (DNP) proteins, suggesting disruption of proteostasis leading to oxidative stress (p = 0.06, [Figure 6](#fig6){ref-type="fig"}H). Finally, we examined UPR by measuring the ratios between the phospho-active forms and total levels of PERK, eIF2α, and IRE1α ([@bib55]), and the downstream targets CHOP and ER-HSP70 BiP ([Figure 6](#fig6){ref-type="fig"}A). Our results showed P-eIF2α/eIF2α and P-IRE1α/IRE1α upregulation in A152T neurons, with further increase in BiP and CHOP levels ([Figure 6](#fig6){ref-type="fig"}J). Even though we did not detect upregulation of P-PERK/PERK, CHOP is a downstream target of P-PERK and P-eIF2α, and transcriptional regulation cannot be excluded. Altogether, these results suggest that protein clearance and UPR are the most affected proteostasis pathways at the early stage of tau accumulation in an A152T iPSC-derived neuronal model.

Selective Vulnerability of A152T Neurons to Stress {#sec2.10}
--------------------------------------------------

Based upon the premise that tauopathy results from time-dependent cumulative cell damage due to buildup of toxic proteins, we asked whether accumulation of tau in A152T neurons was deleterious. If so, by "adding insult to injury" neurons affected by tau accumulation should have lower capacity to survive additional stress ([@bib17], [@bib19]). With the goal of also identifying pathways that may be compromised by tau pathology, we treated 8-week neurons with pathway-specific chemical stressors and compared cell viability between A152T and control neurons ([Figure 7](#fig7){ref-type="fig"}A). These "stressors" included environmental toxins that inhibit the mitochondrial electron transport chain (ETC) complex I (rotenone and piericidin A) ([@bib25], [@bib26]); excitotoxic agonists of the glutamatergic AMPA and/or NMDA receptors (glutamate and NMDA) ([@bib14], [@bib28]); and proteotoxic proteasome inhibitors (MG132 and epoxomicin) and A-β(1--42) amyloid peptide (a predominant component of amyloid plaques in Alzheimer\'s disease) ([@bib48]). To identify conditions whereby control and A152T neurons showed different survival, we started by performing a dose-dependent study in which compounds were added to neuronal cultures at different concentrations for 24 hr and cell viability was measured ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6G). At the concentrations shown in [Figure 7](#fig7){ref-type="fig"}, stressor compounds had minimum impact in control neurons but caused a significant reduction in viability (\<50% viable) of A152T neurons ([Figures 7](#fig7){ref-type="fig"}B, 7D, and 7F). These effects were also detected by IF of MAP2 and NeuN as markers of neuronal integrity, where A152T neurons incubated with mitochondrial ETC inhibitors ([Figure 7](#fig7){ref-type="fig"}C), excitotoxins ([Figure 7](#fig7){ref-type="fig"}E), or proteotoxins ([Figure 7](#fig7){ref-type="fig"}G) showed selective cell loss. These results revealed a phenotype of cellular toxicity suggesting that tau/P-tau accumulation in A152T neurons is associated with increased stress vulnerability, consistent with the observation of altered stress-inducible markers ([Figure 6](#fig6){ref-type="fig"}).

Vulnerability of A152T Neurons to Stress Is Tau Dependent {#sec2.11}
---------------------------------------------------------

To test the direct correlation between upregulation of tau in A152T neurons and increased vulnerability to stress, we examined whether downregulation of the "toxic" tau would be sufficient to rescue viability. First, we genomically engineered the A152T cell line 19-L5-RC6 with CRISPR/Cas9 constructs for targeting and disrupting expression of the *MAPT* gene ([@bib27], [@bib50]). The resulting cell lines (19-L5-RC6;*MAPT*-Kd) revealed a sharp downregulation (≥80%) of tau protein upon differentiation ([Figures S6](#mmc1){ref-type="supplementary-material"}K and S6L), without detectable effect on neuronal integrity ([Figures S6](#mmc1){ref-type="supplementary-material"}M and [S2](#mmc1){ref-type="supplementary-material"}A) or cellular viability ([Figure 7](#fig7){ref-type="fig"}H). Remarkably, upon exposure to the cellular stressors that revealed vulnerability of the parental tau-A152T neurons, we observed a rescue of stress vulnerability in 8-week 19-L5-RC6;*MAPT*-Kd3 neurons, with viability increase to 90%--100%, similar to control ([Figure 7](#fig7){ref-type="fig"}H).

Second, we utilized the mTOR (mammalian target of rapamycin) inhibitor and autophagy activator rapamycin ([@bib4], [@bib46]). In control neurons, rapamycin downregulated tau by ≥50% via activation of the autophagy pathway, as shown by upregulation of the autophagosome marker LC3B-II (Figures S7N--S7P). We then pre-treated 8-week differentiated A152T neurons with rapamycin (8 hr) before exposure to stressor compounds ([Figure 7](#fig7){ref-type="fig"}A). Rapamycin-pre-treated A152T neurons showed a significant increase in cell viability relative to untreated neurons ([Figure 7](#fig7){ref-type="fig"}I). Consistent with the level of tau downregulation, rapamycin caused a milder but consistent rescue of viability compared with genetic knockdown (50% versus \>80%, respectively).

Stress vulnerability tau dependence was further corroborated by testing the same stressors in 2-week neurons ([Figures S6](#mmc1){ref-type="supplementary-material"}H--S6J), before tau accumulation, without a difference in survival between A152T and control neurons.

Altogether, these findings unequivocally demonstrate that accumulation of tau in A152T neurons is coupled to disruption of proteostasis and increased vulnerability to stress, early molecular events leading to neurodegeneration in tauopathy. Our study also demonstrates that endogenous tau-mediated cellular stress can be rescued by compounds that mediate tau clearance, which is of crucial relevance for the use of this cellular model for the development of therapeutics.

Discussion {#sec3}
==========

Human iPSC-derived neurons allow measurement of disease-relevant cellular and molecular phenotypes in a physiologically and genomically relevant context, potentially recapitulating the early stages of disease etiology, and allow direct testing of therapeutic targets and small molecules in a human neuronal environment ([@bib2], [@bib5], [@bib15], [@bib16], [@bib23], [@bib29], [@bib61]). We took advantage of this system to investigate the early events of tau-A152T pathology that may be causal in FTD. Our findings contribute to mounting evidence, across studies of different tau mutations and across model systems, of tau-mediated molecular events associated with neurodegeneration, toward the identification of relevant therapeutic targets ([@bib15], [@bib16], [@bib29], [@bib40], [@bib12], [@bib47], [@bib56], [@bib61]). We biochemically profiled neurons derived from control and A152T carriers, and report on a phenotyping platform for tau regarding protein levels, PTMs, and solubility. We demonstrate accumulation of endogenous tau/P-tau in A152T human neurons by multiple powerful methods. By western blot we found a significant upregulation of P-tau in all A152T neurons, whereas total tau upregulation was specific to the FTD19-derived neurons, consistent with previous reports ([@bib16], [@bib56]). This result might be a consequence of variability among individuals of the same *MAPT* genotype, and possibly the clinical outcome, but only future analysis of larger cohorts of cases could allow us to draw accurate conclusions. By MS analysis we verified upregulation of absolute levels of endogenous tau in A152T neurons that became accentuated with time. By targeted MS, we demonstrated differential levels of tau A152T versus the non-mutant form in A152T neurons, which is relevant to the identification of "the toxic species." Even though this ratio (∼60% versus 40%, respectively) was constant during the period of time tested ([Figure 4](#fig4){ref-type="fig"}C), the gradual increase in total tau ([Figure 4](#fig4){ref-type="fig"}B), suggests that this amount of tau-A152T is sufficient to cause some imbalance that leads to overall accumulation of tau.

By IF we detected an overall increase in tau in A152T neurons, with particular accumulation of P-tau in the cell body, consistent with somatodendritic redistribution of tau, as described for tauopathies and Alzheimer's disease ([@bib11], [@bib16], [@bib39], [@bib56]). We did not detect A152T-specific changes in cell morphology, as reported in another A152T model ([@bib16]), which may be due to differences in methodologies and line-specific variability. Nonetheless, the overall conclusion of tau accumulation, somatodendritic redistribution, and tau-mediated neuronal toxicity in A152T cells was a common observation, unmasked either by additional stress ([Figure 7](#fig7){ref-type="fig"}) or by genetic manipulation (A152T homozygous line in [@bib16]). Taken together, these two studies are complementary by demonstrating that even with technical variability, key aspects in pre-clinical disease events were corroborated.

We also reveal here, for an FTD A152T proband-derived neuronal culture, a decrease in tau solubility, again most accentuated for P-tau. Although we did not detect tau puncta-like aggregates per se, Triton X-insoluble tau and the HMW species detected are consistent with oligomeric species of reduced solubility. Based on our findings we propose a model in which accumulation of P-tau and oligomeric tau of reduced solubility are early disease-causal phenotypes, consistent with other A152T animal models demonstrating tau-mediated toxicity independent of aggregation ([@bib40], [@bib47]).

To explore the mechanisms of tau-mediated toxicity, we focused on specific proteostasis pathways shown previously to be involved in tauopathy, including the HSP70/HSP90 chaperone machinery ([@bib7]), UPR markers ([@bib55]), mitochondrial function and oxidative stress ([@bib49]), and autophagy ([@bib58]). We report on disruption of the UPS and autophagy pathways, in addition to UPR and oxidative stress induction, in A152T neurons. Disruption of protein clearance is a strong model for tau-mediated toxicity in neurodegeneration, and is consistent with the observed accumulation of total tau protein. Also consistent with our findings, a recent study identified alterations of the endosomal-lysosomal pathway associated with another tau mutation ([@bib61]); yet another study identified LAMP1 and ubiquitin as cerebrospinal fluid markers of neurodegeneration, reinforcing the value of our system in the identification of tauopathy biomarkers ([@bib24]). In turn, mounting evidence points to UPR activation "in close connection with early stages of tau pathology" ([@bib1], [@bib54]), and to mitochondrial dysfunction and vulnerability to oxidative stress as common aspects in iPSC-derived models of tauopathy ([@bib15], [@bib29]).

Tau-mediated disruption of proteostasis was further revealed by increased sensitivity of A152T neurons to exogenous "stressors," unveiling toxicity phenotypes and pathways that may be affected in the early stages of tau pathology, offering a powerful method for phenotypic profiling of patient-derived neurons. Not all stressor compounds tested affected neuronal viability (not shown), revealing pathway-specific vulnerability. These phenotypes were tau dependent as shown by CRISPR/Cas9-mediated downregulation of *MAPT* expression in A152T neurons, which rescued neuronal stress vulnerability without affecting cell viability or integrity ([Figures 7](#fig7){ref-type="fig"}H and [S6](#mmc1){ref-type="supplementary-material"}M). Most importantly, we demonstrate that stress vulnerability can be rescued pharmacologically by pre-treating neurons with the autophagy activator rapamycin, highlighting the value of this model for small-molecule screening. This is the first time, in a human neuronal cell context and with endogenous tau expression, that a compound has been shown to clear tau and consequently rescue toxicity. This result also further corroborates a model of tauopathy associated with disruption or inefficiency of protein clearance.

The results presented here are consistent with the proposition that the onset of cellular pathology in FTD occurs earlier than clinical manifestations, which has been corroborated by biomarker studies in Alzheimer's disease ([@bib31]). By implementing a panel of biochemical and cellular assays, and a toolbox of compounds that reveal pathways affected by tau toxicity, we demonstrated the power of phenotypic characterization of patient-derived neuronal cells at the pre-clinical level, which is now suitable for mechanistic studies across *MAPT* genotypes. Finally, we show that endogenous tau phenotypes can be pharmacologically rescued, proving the suitability of our patient iPSC-derived neuronal model for screening therapeutic targets and disease-modifying agents relevant to FTD and other tauopathies.

Experimental Procedures {#sec4}
=======================

iPSC, NPC, and Neuronal Cultures {#sec4.1}
--------------------------------

Reprogramming, characterization, and maintenance of iPSCs, and NPC derivation have been described elsewhere (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}) ([@bib63]). NPCs were cultured on polyornithine and laminin (POL)-coated plates, with DMEM/F12-B27 media supplemented with EGF, FGF, and heparin, and passaged with TrypLE (Life Technologies). Approval for work with human subjects\' materials and iPSCs was obtained under IRB-approved protocols at Massachusetts General Hospital/Partners Healthcare (2009P002730) and University of California, San Francisco (10-00234). Neural differentiation was achieved by plating NPCs (passages 30--35) at a density of ∼50,000 cells/cm^2^ on POL plates, with DMEM/F12-B27 media only (no growth factors), and with ½ medium change every 3--4 days.

Protein Analysis by Western Blot {#sec4.2}
--------------------------------

Western blot analysis was performed using the Novex NuPAGE SDS-PAGE Gel System (Invitrogen) and standard immunoblotting techniques (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

LC-MS/MS Analysis {#sec4.3}
-----------------

Absolute abundance of endogenous tau was determined using the FLEX peptide light-to heavy (L/H) ratio as recently described ([@bib41], [@bib52]). The number of independent experiments was three; however, due to inherent challenges with long-term human neuronal differentiated cultures, there was a punctual necessity to pool samples for enough protein material at 20 weeks, for which n = 2 ([Figures 4](#fig4){ref-type="fig"}B--4D). See [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for Expression and Purification of Heavy FLEXITau Standard, FLEXITau Sample Preparation and analysis, spectra analysis, data processing, and FLEXITau liquid chromatography (LC)-SRM measurements.

Analysis of Protein Solubility by Detergent Fractionation {#sec4.4}
---------------------------------------------------------

The analysis was performed according to published protocols (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

*MAPT* Knockdown by CRISPR/Cas9 Genomic Engineering {#sec4.5}
---------------------------------------------------

The *MAPT* gene locus was targeted by the Tau CRISPR/Cas9 KO Plasmid (h) and Tau HDR Plasmid (h) (Santa Cruz Biotechnology sc-400136/sc-400136-HDR) in 19-L5-RC6 NPCs, according to the manufacturer\'s instructions (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

Compound Treatment and Viability Assays {#sec4.6}
---------------------------------------

Compound or vehicle alone was added directly onto the cellular medium. Viability was measured with the Alamar Blue Cell viability reagent (Life Technologies), according to the manufacturer\'s instructions. Readings were done in the EnVision Multilabel Plate Reader (PerkinElmer). For IF, fixed neurons image acquisition was done with the IN Cell Analyzer 6000 Cell Imaging System (GE Healthcare Life Sciences). For further details see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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![Human iPSC-Derived NPCs, and Synaptic and Cortical Markers in NPC-Derived Neurons\
(A) Summary of the experimental strategy followed. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.\
(B) Bright-field and IF analysis of NPC markers (green) in control and A152T lines. Scale bar, 100 μm.\
(C and D) Western blot analysis of cortical layers II--III, V, and VI markers (C) and synaptic proteins (D), in 5-week control and A152T neurons. Human ACC is a positive control for cortical markers. GAPDH is the loading control. Samples ran in the same blot and are cropped for clarity (n ≥ 3 independent experiments). See also [Figure S2](#mmc1){ref-type="supplementary-material"}.\
(E) IF analysis of cortical (I--IV), synaptic (V--VI), glutamatergic (VII), and neuronal (VIII) markers (red) in 5-week neurons (representative of control and A152T). Dotted insets correspond to zoomed-in images. Scale bars, 20 μm. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Time-Dependent Upregulation of Tau in A152T Neurons\
(A and E) Total tau (A) and P-tau (E) expression by western blot analysis of up to 5-week differentiated neurons in control and A152T cell lines. Far-right panels show recombinant tau ladder (six tau isoforms, no PTMs); GAPDH is the loading control (n ≥ 3 independent experiments). Arrows indicate bands quantified: blue for bands with corresponding migration to the tau ladder, green for HMW bands. Samples ran in same blot as far as possible.\
(B--D and F--I) Semi-quantitative analysis of western blots in (A) and (E). Band intensities in a.u. relative to GAPDH, averaged (Avrg) across genotype (controls/gray, A152T/black) ± SEM. Two-way ANOVA and Bonferroni post test, n ≥ 3 independent experiments: ns, not significant (p \> 0.05); ^∗^p \< 0.05, ^∗∗^p \< 0.01.\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Upregulation of Tau in A152T Neurons by IF Analysis\
Total tau (K9JA), P-tau (PHF1), and MAP2 by IF in control and A152T 5-week neurons. Dotted insets correspond to zoomed-in images shown on the right. Scale bars, 50 μm.](gr3){#fig3}

![Tau Profile by MS Analysis\
(A) Workflow for preparation of control (8330-8-RC1) and A152T (19-L5-RC6) samples for MS analysis.\
(B) Quantification of total endogenous tau by FLEXITau. Shown is average tau in fmol/μg of protein lysate ± SD (n = 3, except n = 2 for week 20, see [Experimental Procedures](#sec4){ref-type="sec"}).\
(C) Relative amount of endogenous non-mutant tau and A152T tau in control and A152T neurons (mean ± SD, n = 3, except n = 2 for week 20, see [Experimental Procedures](#sec4){ref-type="sec"}).\
(D) Global quantitative peptide profile by FLEXITau, relative to full-length 2N4R-tau. Shown is the normalized amount of unmodified peptides relative to heavy tau protein standard (mean ± SD, n = 3 independent experiments). ^∗^p \< 0.05, Student's t test.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Detection of Insoluble Tau in A152T Neurons\
(A) Western blot analysis of total tau (TAU5) and P-tau (S396, AT8) in Triton X (T)-soluble and Triton-X-insoluble SDS (S) fractions from 5-week neurons. GAPDH is the loading control.\
(B) Semi-quantitative analysis of S-fraction band intensities from (A), relative to GAPDH in T-fraction (AU, arbitrary units). Values averaged between control, FTD19, and Tau6 lines (±SEM, n ≥ 3 independent experiments; ^∗^p ≤ 0.05, ^∗∗∗^p ≤ 0.001, Student's t test).](gr5){#fig5}

![Enhanced Stress Markers in A152T Neurons\
(A) Simplified representation of proteostasis pathways responsive to proteotoxic stress (blue denotes components measured).\
(B--J) Western blot and semi-quantitative analysis, in 8-week control and A152T neurons, of: (B and F) polyubiquitinated (UBI1), macro-autophagy (LC3B, SQSTM1/p62, ATG12-ATG5), and chaperone-mediated autophagy (LAMP1, LAMP2a) proteins; (C and G) molecular chaperones (HSP70, HSP90) and HSP70 co-chaperones (CHIP, HIP, HOP) of the HSR; (D and H) polycarbonylated proteins (DNP-derived); (E and J) UPR activation of PERK, eIF2α, and IRE1α, and downstream targets CHOP and BiP; (D and I) tau (DA9) and P-tau (PHF1). Shown is mean band intensity (±SD) relative to GAPDH; n = 3 independent experiments. Student's t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001; ns, not significant.](gr6){#fig6}

![Increased Vulnerability to Stress in A152T Neurons Is Tau Dependent\
(A) Overview of the stress vulnerability tests done in 8-week neurons (a) using high doses of stress, (b) pre-treating neurons with the autophagy inducer rapamycin, or by testing genetically engineered *MAPT*-Kd neurons.\
(B, D, and F) Cell viability of 8-week neurons, treated with compounds for 24 hr. Values represent percent viability (±SEM) relative to vehicle-treated neurons. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, two-way ANOVA and Bonferroni post test (n ≥ 3 independent experiments).\
(C, E, and G) IF analysis of neuronal integrity of control (CTR2-L17-RC2) and A152T (19-L3-RC3) neurons upon 24-hr treatment, based on MAP2/NeuN staining. Scale bars 50 μm.\
(H) Cell viability of 8-week neurons upon 24-hr treatment. The genetically engineered line *MAPT*-Kd3 (19-L5-RC6;*MAPT*-Kd3) showed rescue of vulnerability to stress relative to A152T neurons. Percent viability (±SEM) is relative to vehicle-treated cells (100%). Two-way ANOVA and Bonferroni post test: ^∗^p \< 0.05, ^∗∗∗^p \< 0.001; ns, not significant (p \> 0.05) (n ≥ 3 independent experiments).\
(I) Rescue of A152T neuronal (19-L5-RC6) vulnerability to stress \[24 hr of rotenone, NMDA, and Aβ(1--42)\] by 8-hr pre-treatment of neuronal cultures with rapamycin (RAP, 5 μM). Percent viability (±SEM) is relative to vehicle-treated cells (100%). Student's t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p ≤ 0.001; ns, not significant (p \> 0.05) (n ≥ 3 independent experiments).\
See also [Figure S6](#mmc1){ref-type="supplementary-material"}.](gr7){#fig7}
